Castle Biosciences Q2 revenue $50.1M (+44% YoY); raises FY 2023 guidance to at least $180M

CASTLE BIOSCIENCES INC

2023-Q2 EPS reported -$1.80 revenue$92,175,000

Q2 revenue $50.1M (+44% YoY); adjusted revenue $50.2M (+47%).
Total test reports 16,820 (+52%); DecisionDx-SCC +99%, TissueCypher +311%, IDgenetix +224%.
Net loss $(18.8)M includes $12.8M stock comp; adjusted EBITDA improves to $(5.3)M from $(11.2)M.
Raises 2023 revenue guidance to at least $180M from prior $170-180M.
Cash and investments $225.5M; net operating cash use improved to $3.8M from $9.0M.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

CASTLE BIOSCIENCES INC reported second quarter and six months ended June 30, 2023 results: revenue $50.1 million, net income $(18.8) million. Guidance raised.

Period: second quarter and six months ended June 30, 2023
Revenue: $50.1 million
Net income: $(18.8) million
Guidance: raised
Result: reported results

Exact text from the filing

such filing to this Current Report on Form 8-K. --- EX-99.1 (EX-99.1) --- Castle Biosciences Reports Second Quarter 2023 Results Q2 2023 revenue increased 44% over Q2 2022 to $50 million Q2 2023 total test reports increased 52% over Q2 2022 Raising full year 2023 revenue guidance to at least $180 million from $170-180 million Conference call and webcast today at

View on SEC.gov

Browse all earnings releases →

CASTLE BIOSCIENCES INC filing history →

Source: SEC EDGAR

accession 0001447362-23-000127

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.